trending Market Intelligence /marketintelligence/en/news-insights/trending/SIiB03E8Q8QpPRYXdoNmJA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Sienna Biopharmaceuticals' asset sale plan wins nod from US bankruptcy court

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Sienna Biopharmaceuticals' asset sale plan wins nod from US bankruptcy court

Sienna Biopharmaceuticals Inc., which previously filed for Chapter 11 bankruptcy protection, said the U.S. Bankruptcy Court for the District of Delaware approved the sale of its assets, including intellectual property, related to its experimental drug SNA-001.

The Westlake Village, Calif.-based biopharmaceutical company it will auction assets related to its experimental hair removal treatment, which uses a topical solution of silver photoparticles, for $1.7 million cash.

Following the court's approval, Sienna has requested the Nasdaq Stock Market to delist its shares from Dec. 13.

In November, the court approved Sienna's proposed bidding procedures.

The biopharmaceutical company, which develops therapies in immunology and inflammation that target select pathways in tissues, has previously said it continues to operate its business under the jurisdiction of the same bankruptcy court and according to the provisions of the bankruptcy code.